High dose off-label Safinamide treatment in Young Onset Parkinson’s Disease patients
Objective: To assess tolerability and efficacy of high dose Safinamide treatment in Young Onset Parkinson’s Disease (YOPD) patients with dystonia and history of impulse controls…Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients
Objective: To evaluate the clinical effects of safinamide, administered as add-on therapy to levodopa in fluctuating PD patients, on symptoms severity and daily living. Background:…Opicapone added to safinamide in patients affected by Parkinson’s disease for better controlling motor fluctuations
Objective: The aim of this clinical observation was to verify the sparing of levodopa in patients affected by Parkinson's disease who already started safinamide treatment for…Safinamide: real world evidence in Toledo´s Movement Disorders Unit
Objective: We present a prospective observational-real life study about the use of safinamide in Movement Disorders Unit´s patients. Background: The gold standard of pharmacological treatment…Addition of Opicapone to Safinamide in Parkinson’s Disease patients
Objective: To assess safety and efficacy of Opicapone in patients treated with Levodopa and Safinamide presenting early morning “off” states and akinesia. Background: Safinamide is…SAFINAMIDE IN DAILY CLINICAL PRACTICE: ASSESSMENT OF EFFICACY AND TOLERABILITY IN PARKINSON´S DISEASE
Objective: to analyze the long term efficacy and tolerability of safinamide added as adjunctive therapy in a series of patients with Parkinson´s disease (PD) Background:…Evolution of anti-parkinsonian drug prescribing patterns in Parkinson’s disease
Objective: To compare Parkinson’s disease (PD) treatment practices by movement disorder (MD) specialists across a decade, and to determine the factors that influence drug choice…Effects of safinamide and rasagiline on in vivo glutamate release in 6-OHDA hemilesioned rats
Objective: To investigate the effects of safinamide (saf) and rasagiline on in vivo glutamate (Glu) release in the 6-hydroxydopamine (6-OHDA) hemilesioned rat model of Parkinson’s…Safinamide in the treatment of URINARY symptoms in PARKinson’s disease (SURINPARK)
Objective: We compared the effects of safinamide on the urinary symptoms of Parkinson's disease with other therapies. Background: Urinary symptoms (US) are common, disabling and…Safinamide in Parkinson’s disease
Objective: To evaluate clinical effects, safety and tolerability of safinamide add-on levodopa in Parkinson’s disease (PD) patients. Background: Safinamide is a recently approved adjunctive treatment…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.